Lupin Looks To Be First Out Of The Blocks On US Ingrezza, With Zydus Second

US Ingrezza Legal Battles Wrapped Up, With Earlier Teva, Sandoz Deals

ANDA sponsors targeting Neurocrine Biosciences’ Ingrezza (valbenazine) blockbuster are in position to launch – albeit with a 14-year wait that validates the strength of the originator’s IP.

Enter The Fray
• Source: Alamy

Lupin will look to enjoy a seven-month advantage over its rival Indian firm Zydus Lifesciences in the race to debut generic competition to Neurocrine Biosciences’ Ingrezza (valbenazine) treatment for tardive dyskinesia in the US, after both companies in quick succession penned patent-litigation settlements.

Picking up the right to launch its proposed generic beginning 1 March 2038, Lupin faces a 14-year wait to launch...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Products

One Month Remains To Enter GGB Awards 2025

 
• By 

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.

Advanz Claims Cimzia Biosimilar In Europe Following Alvotech-Xbrane Deal

 
• By 

A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.

Biocon Biologics’ Yesafili Approved And Ready To Launch In Canada

 

Canada will welcome its first Eylea off-patent rival in July, as Biocon Biologics celebrates the commercialization of its 10th biosimilar worldwide.